Parabolic Drugs Ltd
PARABDRUGS Share Price
PARABDRUGS Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
LowProfitability and efficiency haven't been upto the mark
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
PARABDRUGS Performance & Key Metrics
PARABDRUGS Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| — | -0.04 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.59 | 6.40 | 0.79% |
PARABDRUGS Analyst Ratings & Forecast
Price Upside
Earnings Growth
Rev. Growth
PARABDRUGS Company Profile
Parabolic Drugs Limited is an integrated, research-based, pharmaceutical manufacturer and exporter, engaged in development and manufacturing of Active Pharmaceutical Ingredients (API) and API intermediates.
PARABDRUGS Forecast
PARABDRUGS Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
PARABDRUGS
PARABDRUGS
Income
Balance Sheet
Cash Flow
PARABDRUGS Income Statement
PARABDRUGS Income Statement
| Financial Year | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 928.42 | 772.88 | 450.63 | 233.38 | 77.16 | 81.10 | 77.32 | 18.89 | 0.02 | — | ||||||||||
Raw Materials | 800.45 | 691.04 | 391.42 | 209.02 | 59.07 | 64.87 | 64.60 | 34.72 | 6.41 | — | ||||||||||
| Power & Fuel Cost | 9.81 | 10.02 | 17.22 | 15.26 | 10.17 | 8.97 | 6.87 | |||||||||||||
| Employee Cost | 22.52 | 23.75 | 19.23 | 17.46 | 10.91 | 9.03 | 9.83 | |||||||||||||
| Selling & Administrative Expenses | 23.31 | 25.55 | 20.69 | 14.06 | 8.69 | 6.07 | 5.77 | |||||||||||||
| Operating & Other expenses | -89.09 | 94.75 | 72.20 | 55.52 | 294.74 | 32.58 | 2.20 | |||||||||||||
EBITDA | 161.42 | -72.23 | -70.13 | -77.94 | -306.42 | -40.42 | -11.95 | -15.83 | -6.39 | — | ||||||||||
| Depreciation/Amortization | 30.85 | 55.19 | 68.25 | 73.20 | 67.22 | 53.65 | 34.54 | 22.52 | 21.59 | — | ||||||||||
| PBIT | 130.57 | -127.42 | -138.38 | -151.14 | -373.64 | -94.07 | -46.49 | -38.35 | -27.98 | — | ||||||||||
| Interest & Other Items | 64.14 | 73.24 | 83.70 | 98.99 | 107.62 | 10.97 | 9.30 | 3.46 | 0.66 | — | ||||||||||
| PBT | 66.43 | -200.66 | -222.08 | -250.13 | -481.26 | -105.04 | -55.79 | -41.81 | -28.64 | — | ||||||||||
| Taxes & Other Items | 15.23 | -56.17 | -88.28 | 130.32 | 4.43 | 3.05 | 1.76 | -0.41 | 0.00 | — | ||||||||||
| Net Income | 51.20 | -144.49 | -133.80 | -380.45 | -485.69 | -108.09 | -57.55 | -41.40 | -28.64 | — | ||||||||||
| EPS | 8.27 | -23.35 | -21.62 | -61.47 | -78.47 | -17.46 | -9.30 | -6.57 | -4.63 | — | ||||||||||
| DPS | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | ||||||||||
| Payout ratio | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
PARABDRUGS Company Updates
PARABDRUGS Stock Peers
PARABDRUGS Past Performance & Peer Comparison
PARABDRUGS Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Parabolic Drugs Ltd | -1.19 | -0.04 | — |
| Sun Pharmaceutical Industries Ltd | 36.50 | 5.50 | 0.96% |
| Cipla Ltd | 22.64 | 3.82 | 1.08% |
| Torrent Pharmaceuticals Ltd | 59.13 | 14.89 | 0.18% |
PARABDRUGS Stock Price Comparison
Compare PARABDRUGS with any stock or ETFPARABDRUGS Holdings
PARABDRUGS Shareholdings
PARABDRUGS Promoter Holdings Trend
PARABDRUGS Promoter Holdings Trend
PARABDRUGS Institutional Holdings Trend
PARABDRUGS Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
PARABDRUGS Shareholding Pattern
PARABDRUGS Shareholding Pattern
PARABDRUGS Shareholding History
PARABDRUGS Shareholding History
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing PARABDRUGS stock
smallcases containing PARABDRUGS stock
Looks like this stock is not in any smallcase yet.
PARABDRUGS Events
PARABDRUGS Events
PARABDRUGS Dividend Trend
PARABDRUGS has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
PARABDRUGS Dividend Trend
PARABDRUGS has not given any dividends in last 5 years
PARABDRUGS Upcoming Dividends
PARABDRUGS Upcoming Dividends
No upcoming dividends are available
PARABDRUGS Past Dividends
PARABDRUGS Past Dividends
Cash Dividend
Ex DateEx DateSep 24, 2012
Dividend/Share
₹0.25
Ex DateEx Date
Sep 24, 2012
Cash Dividend
Ex DateEx DateSep 19, 2011
Dividend/Share
₹0.50
Ex DateEx Date
Sep 19, 2011
PARABDRUGS Stock News & Opinions
PARABDRUGS Stock News & Opinions
Rs 1,626 Crore Money Laundering Case: Ashoka University Co-Founders Sent To 5 Days Remand
Bank Fraud: ED Arrests Two Promoters, CA Of Parabolic Drugs In Money Laundering Case
Have nothing to do with CBI’s investigation of co-founders: Ashoka University
Parabolic Drugs reports standalone net loss of Rs 0.06 crore in the December 2020 quarter
BRIEF-Parabolic Drugs Says Shares Of Co Cancelled Without Any Payout To Shareholders
Parabolic Drugs reports standalone net loss of Rs 7.22 crore in the March 2020 quarter
In last 6 months, promoter holding in the company has almost stayed constant
A significant proportion of promoter holdings is pledged